Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with non-small cell lung cancer (NSCLC) at Stage III or IV, where treatment is focused on managing the disease rather than curing it
- Adults aged 18 years or older
- People whose general health and ability to carry out daily activities falls within a certain range (confirm with trial site for specific fitness level requirements)
- People whose cancer has been stable — meaning no signs of the cancer growing or spreading in the last three months
- People who experience breathlessness that is at least moderately bothersome, as measured by a standard breathlessness rating scale
- People who are fluent in written and spoken English
Who may not be able to join:
- People whose lung cancer is being treated with the aim of a cure, including those receiving chemotherapy and radiation together for locally advanced or limited-spread NSCLC
- People whose cancer is currently showing signs of growing or spreading
- People whose cognitive or mental health difficulties would prevent them from completing the study requirements
- People assessed as having a high risk of bone fracture or spine instability, based on specific medical scoring tools (confirm with trial site)
- People with moderate to severe heart failure
- People who have had a heart attack, unstable chest pain, a heart procedure, or a stent placed in the six months before starting radiation therapy
- People with irregular heart rhythms that are not well controlled
- People who have experienced episodes of fainting
- People with active inflammation of the heart or its surrounding tissues
- People who have had a blood clot in the lungs in the last three months
- People who have had a blood clot in the legs in the last three months
- People with a suspected tear in a major blood vessel
- People with fluid build-up in the lungs
- People experiencing respiratory failure
- People with any other non-heart or lung condition that may be affected by or interfere with exercise
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Melinda Hsu, MD, MS, Case Comprehensive Cancer Center, University Hospitals
Phone: 216-286-6505
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in functional capacity of LCS with advanced NSCLC, as measured by the 6-minute walk test (6MWT); Change in self-reported dyspnea and quality of life (QoL) in LCS with advanced NSCLC, as measured by the modified Borg scale (MBS); Change in self-reported dyspnea and quality of life (QoL) in LCS with advanced NSCLC, as measured by the EORTC QLQ-C30; Change in self-reported dyspnea and quality of life (QoL) in LCS with advanced NSCLC, as measured by the EORTC QLQ-LC29; Change in quantity of cancer-related adverse events (AEs), as measured by the Patient-Reported Outcomes version of the Comm...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.